Postmenopausal tamoxifen treatment and endometrial pathology

Cohen I, I Cohen, Altaras MM, M M Altaras, J Shapira, Shapira J, R. Tepper, Tepper R, Y Beyth, Beyth Y
Obstetrical & gynecological survey · 1994 · vol. 49(12) , pp. 823–9 · doi:10.1097/00006254-199412000-00006 · PMID:7885659
Review OA: closed
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-25 ⓘ

This review examines the accumulating data and clinical experience regarding the association between endometrial pathologies and postmenopausal tamoxifen treatment for breast cancer, recommending close patient supervision.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-25 · read from full text ⓘ

This review examines the accumulating data regarding the association between postmenopausal tamoxifen treatment and various endometrial pathologies in breast cancer patients. The authors analyze current literature alongside their own clinical experience to highlight potential risks associated with this adjuvant therapy for estrogen receptor-positive cases. They explicitly recommend close medical supervision of these patients due to the observed link between the drug and uterine changes. This paper is centrally about endometriosis and adenomyosis research, as it directly investigates the endometrial pathology risks associated with a common hormonal medication used in women's health.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Tamoxifen is widely used as adjuvant therapy for postmenopausal breast cancer patients with positive estrogen receptors. Data on a possible association of endometrial pathologies with tamoxifen treatment have been accumulating. In this review, we examine the current literature and include our own experience with this occurrence. We recommend close supervision of these patients.
Full text 664 characters · extracted from oa-doi-fallback · click to expand
REVIEW: PDF Only Postmenopausal Tamoxifen Treatment and Endometrial Pathology - Ilan Cohen - Marco M. Altaras - Jeremiah Shapira - Ronnie Tepper - Yoram Beyth Obstetrical & Gynecological Survey 49(12):p 823-829, December 1994. Tamoxifen is widely used as adjuvant therapy for postmenopausal breast cancer patients with positive estrogen receptors. Data on a possible association of endometrial pathologies with tamoxifen treatment have been accumulating. In this review, we examine the current literature and include our own experience with this occurence. We recommend close supervision of these patients. Copyright © Williams & Wilkins 1994. All Rights Reserved.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Breast Endometrial Hyperplasia Endometrial Neoplasms Endometriosis Endometrium Postmenopause Tamoxifen Tamoxifen Breast Breast Breast Neoplasms Breast Neoplasms Clinical Trials as Topic Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
pubmed
last seen: 2026-10-08T21:59:07.256998+00:00
unpaywall
last seen: 2026-10-08T06:33:43.470499+00:00